Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Evogene (EVGN) over the last 10 years, with Q2 2025 value amounting to $15.2 million.

  • Evogene's Total Current Liabilities fell 669.94% to $15.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $15.2 million, marking a year-over-year decrease of 669.94%. This contributed to the annual value of $18.7 million for FY2024, which is 16922.52% up from last year.
  • According to the latest figures from Q2 2025, Evogene's Total Current Liabilities is $15.2 million, which was down 669.94% from $18.7 million recorded in Q4 2024.
  • In the past 5 years, Evogene's Total Current Liabilities registered a high of $18.7 million during Q4 2024, and its lowest value of $5.3 million during Q2 2021.
  • Over the past 5 years, Evogene's median Total Current Liabilities value was $6.9 million (recorded in 2021), while the average stood at $9.7 million.
  • As far as peak fluctuations go, Evogene's Total Current Liabilities crashed by 2887.56% in 2021, and later soared by 16922.52% in 2024.
  • Over the past 5 years, Evogene's Total Current Liabilities (Quarter) stood at $6.9 million in 2021, then fell by 18.27% to $5.6 million in 2022, then increased by 23.45% to $6.9 million in 2023, then surged by 169.23% to $18.7 million in 2024, then dropped by 18.73% to $15.2 million in 2025.
  • Its last three reported values are $15.2 million in Q2 2025, $18.7 million for Q4 2024, and $16.3 million during Q2 2024.